α-synuclein seed amplification assay positivity is associated with motor progression in the prodromal stage independent of phenoconversion
Background: α-Synuclein seed amplification assay (αSyn-SAA) has emerged as a promising biomarker for detecting underlying α-synuclein pathology and predicting phenoconversion in prodromal Parkinson's disease (PD). However, its association with longitudinal clinical progression during the prodromal stage remains unclear. We investigated whether baseline αSyn-SAA status and kinetic parameters were associated with motor and cognitive progression and subsequent phenoconversion in prodromal individuals. Methods: Clinical progression was assessed using the Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III motor scores, Hoehn and Yahr (H&Y) stage, and Montreal Cognitive Assessment (MoCA) scores. Linear mixed-effects models were utilized to examine the associations between baseline αSyn-SAA status, kinetic parameters, and longitudinal changes in these clinical measures. Additionally, time-to-event analyses were performed to assess the associations between SAA measurements and phenoconversion to PD or dementia with Lewy bodies. Results: We identified 2,532 participants with available baseline αSyn-SAA status in the Parkinson's Progression Markers Initiative (PPMI) prodromal cohort. This longitudinal study, which included up to 12 years of follow-up, comprised 1,714 αSyn-SAA-positive and 818 αSyn-SAA-negative individuals. Over the follow-up period, αSyn-SAA-positive participants exhibited significantly faster motor progression measured by MDS-UPDRS Part III motor score than αSyn-SAA-negative participants (0.611 vs. 0.139 points/year; P<0.001). This association persisted after excluding phenoconverters (0.430 vs. 0.202 points/year; P=0.014) and restricting follow-up to seven years (0.588 vs. 0.137 points/year; P<0.001). Among the 1,796 participants included in the time-to-event analyses, 181 phenoconversion events occurred. Baseline αSyn-SAA positivity was associated with a significantly higher hazard of phenoconversion (adjusted hazard ratio 5.72, 95% confidence interval 3.78-8.68; P<0.001), whereas kinetic parameters showed no significant associations with phenoconversion risk. Conclusions: Baseline αSyn-SAA positivity was associated with accelerated motor progression during the prodromal stage independent of phenoconversion. These findings support the potential utility of αSyn-SAA positivity as a prognostic biomarker for motor progression and phenoconversion, with implications for risk stratification and participant selection in future disease-modifying trials.
Authors
- Bin Xiao (ORCID: https://orcid.org/0000-0003-2986-4980)
- Jing Han Ng
- Eng‐King Tan (ORCID: https://orcid.org/0000-0003-2977-9743)
- Prakash Kumar Manharlal
- Seyed Ehsan Saffari (ORCID: https://orcid.org/0000-0002-6473-4375)
- Louis Tan
- Mahsa Zeynali
- Xiao Deng
- Shermyn Neo Xiumin
Institutions
- National University of Singapore (SG)
- Duke-NUS Medical School (SG)
- National Neuroscience Institute (SG)
Publication Details
- Journal
- medRxiv
- Published
- 2026-11-18
- DOI
- https://doi.org/10.64898/2026.11.16.26368235
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- preprint